Although the benefit seen in the CAVE study needs Phase III confirmation, the analysis showed that plasma ctDNA testing may help identify best responders.
The Phase II study will assess the antibody-drug conjugate patritumab deruxtecan for previously treated colorectal cancer patients expressing varying levels of HER3.
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.
The firm said its genetic tests for breast, prostate, and colorectal cancers and melanoma assess a patient's personal cancer risks and guide personalized prevention.
The company, which uses fruit fly "avatars" to screen drugs, will be collaborating with London IVD Co-operative and Genomics England to test their technology in GI cancer patients.
The researchers said their new study supports the clinical utility of their test, which combines genomic and drug screening analyses of organoids to guide cancer treatment.
